Literature DB >> 15024141

Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis.

W Armbrust, S S M Kamphuis, T W F Wolfs, T J W Fiselier, P G Nikkels, W Kuis, N M Wulffraat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15024141     DOI： 10.1093/rheumatology/keh074

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  13 in total

Review 1.  Update on the medical treatment of juvenile idiopathic arthritis.

Authors:  Philip J Hashkes; Ronald M Laxer
Journal:  Curr Rheumatol Rep       Date:  2006-12       Impact factor: 4.592

2.  [Biologics for treatment of juvenile idiopathic arthritis. Consensus statement of the 7th Wörlitzer Expertengespräche 2004 for the German Arbeitsgemeinschaft Kinder- und Jugendrheumatologie].

Authors:  G Horneff
Journal:  Z Rheumatol       Date:  2006-03       Impact factor: 1.372

Review 3.  [Importance of the new biologicals and cytokine antagonists in the treatment of juvenile idiopathic arthritis (JIA)].

Authors:  G Horneff
Journal:  Z Rheumatol       Date:  2005-06       Impact factor: 1.372

4.  Serious musculoskeletal infections in children receiving anti-tumor necrosis factor-alpha therapy: a case series.

Authors:  Kimberly Morishita; Ross Petty; Robyn Cairns; Roxana Bolaria; David Cabral; Stuart Turvey
Journal:  Clin Rheumatol       Date:  2010-04-10       Impact factor: 2.980

Review 5.  The safety profile of biologic therapies for juvenile idiopathic arthritis.

Authors:  Philip J Hashkes; Yosef Uziel; Ronald M Laxer
Journal:  Nat Rev Rheumatol       Date:  2010-08-31       Impact factor: 20.543

Review 6.  Ocular complications associated with systemic medications used in allergy/immunology practice.

Authors:  Avinash Gurbaxani; Clare L Fraser; Simon E Skalicky; Peter McCluskey
Journal:  Curr Allergy Asthma Rep       Date:  2013-06       Impact factor: 4.806

Review 7.  Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature.

Authors:  Sima S Toussi; Nancy Pan; Heather M Walters; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2013-07-29       Impact factor: 9.079

Review 8.  Infliximab therapy in children and adolescents with inflammatory bowel disease.

Authors:  Gabor Veres; Robert N Baldassano; Petar Mamula
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors.

Authors:  Heather M Walters; Nancy Pan; Thomas J A Lehman; Alexa Adams; Wei-Ti Huang; Lemonia Sitaras; Susanna Cunningham-Rundles; Thomas J Walsh; Sima S Toussi
Journal:  Clin Rheumatol       Date:  2014-09-18       Impact factor: 2.980

10.  Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.

Authors:  Matthew L Stoll; Alisa C Gotte
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.